As previously disclosed in the Current Report on Form 8-K filed by ABIOMED, Inc. (Company), with the U.S. Securities and Exchange Commission (the “SEC”) on November 1, 2022, the Company is party to an Agreement and Plan of Merger, dated as of October 31, 2022 (the “Merger Agreement”), with Johnson & Johnson and Athos Merger Sub, Inc. In addition, effective as of the closing of the Merger, the employment with the Company of each of Michael R. Minogue, the Company's Chief Executive Officer, terminated. Each such termination of employment constituted a termination without “Cause” under the respective individual's change of control agreement (and, in the case of Mr. Minogue, the letter agreement entered into with the Company in connection with the Company's entry into the Merger Agreement).